NCT07168655Completed
Mavacamten in Obstructive Hypertrophic Cardiomyopathy
Real-World Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten - a Single-Center Descriptive Study
Source: ClinicalTrials.gov · Last updated 11 Sept 2025
Brief summary (registry, in English)
The purpose of this study is to evaluate the real-world outcomes of individuals diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) treated with mavacamten at the Hospital of The University of Pennsylvania in the US
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 163 (actual)
- First submitted
- 23 Jul 2025
- Start date
- 21 Feb 2023
- Primary completion date
- 31 Mar 2023
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Hypertrophic cardiomyopathy
- NCT number
- NCT07168655
What you commit to
- Study type: Observational
- Participants enrolled: 163
- From 21 Feb 2023 to the primary completion date, 31 Mar 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current participation in a myosin inhibitor clinical trial
Other
- Data collection as part of a clinical trial during the study period
Who the study is looking for
- Age ≥ 18 years at index date
- Prescription of mavacamten for the treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM)
- ≥ 4 weeks of follow-up after prescription of mavacamten
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.